{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:40:08Z","timestamp":1718368808993},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Natural Scientific Foundation","award":["2012B031800073"],"award-info":[{"award-number":["2012B031800073"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jss.2016.08.014","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T18:37:40Z","timestamp":1470940660000},"page":"371-379","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor"],"prefix":"10.1016","volume":"206","author":[{"given":"Chang-Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2016.08.014_bib1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2016.08.014_bib2","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jss.2016.08.014_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jss.2016.08.014_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2016.08.014_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jss.2016.08.014_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1349-7006.2009.01082.x","article-title":"Clinically relevant radioresistant cells efficiently repair DNA double-strand breaks induced by X-rays","volume":"100","author":"Kuwahara","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jss.2016.08.014_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000346222","article-title":"Surgical strategy for liver cancers in the era of effective chemotherapy","volume":"2","author":"Shindoh","year":"2013","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jss.2016.08.014_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature04874","article-title":"Mechanisms of drug inhibition of signalling molecules","volume":"441","author":"Sebolt-Leopold","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jss.2016.08.014_bib9","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-09-3182","article-title":"Targeting multiple kinase pathways: a change in paradigm","volume":"16","author":"Gossage","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jss.2016.08.014_bib11","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jss.2016.08.014_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2016.08.014_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2016.08.014_bib14","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","article-title":"The role of signaling pathways in the development and treatment of hepatocellular carcinoma","volume":"29","author":"Whittaker","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jss.2016.08.014_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/15680096113139990076","article-title":"P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives","volume":"13","author":"Binkhathlan","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jss.2016.08.014_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1476-4598-11-85","article-title":"Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells","volume":"11","author":"Grabinski","year":"2012","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jss.2016.08.014_bib17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/hep.23470","article-title":"Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in\u00a0vitro and in mouse model systems","volume":"51","author":"Hennig","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jss.2016.08.014_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2011.12.043","article-title":"Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling","volume":"319","author":"Fujimaki","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jss.2016.08.014_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jss.2016.08.014_bib20","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1016\/j.yexcr.2006.09.005","article-title":"P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines","volume":"312","author":"Solazzo","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jss.2016.08.014_bib21","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.18632\/oncotarget.1236","article-title":"The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy","volume":"4","author":"Simioni","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.jss.2016.08.014_bib22","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/1535-7163.MCT-10-0062","article-title":"MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in\u00a0vitro and in\u00a0vivo","volume":"9","author":"Henderson","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jss.2016.08.014_bib23","first-page":"4951","article-title":"PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras\/Raf\/MAPK and PI3K\/AKT\/mTOR pathways","volume":"30","author":"Gedaly","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.7150\/jca.12452","article-title":"Vertical targeting of AKT and mTOR as well as dual targeting of AKT and MEK signaling is synergistic in hepatocellular carcinoma","volume":"6","author":"Ewald","year":"2015","journal-title":"J Cancer"},{"key":"10.1016\/j.jss.2016.08.014_bib25","first-page":"1709","article-title":"Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS\/RAF\/MAPK and WNT\/beta-catenin pathways","volume":"34","author":"Galuppo","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.110.175786","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","volume":"337","author":"Chen","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jss.2016.08.014_bib27","first-page":"2531","article-title":"The role of PI3K\/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment","volume":"32","author":"Gedaly","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jss.2011.10.045","article-title":"PKI-587 and sorafenib targeting PI3K\/AKT\/mTOR and Ras\/Raf\/MAPK pathways synergistically inhibit HCC cell proliferation","volume":"176","author":"Gedaly","year":"2012","journal-title":"J Surg Res"},{"key":"10.1016\/j.jss.2016.08.014_bib29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/onc.2009.403","article-title":"Sorafenib, a dual Raf kinase\/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs","volume":"29","author":"Ramakrishnan","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jss.2016.08.014_bib30","doi-asserted-by":"crossref","first-page":"e61603","DOI":"10.1371\/journal.pone.0061603","article-title":"Sorafenib inhibits lymphoma xenografts by targeting MAPK\/ERK and AKT pathways in tumor and vascular cells","volume":"8","author":"Carlo-Stella","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jss.2016.08.014_bib31","doi-asserted-by":"crossref","first-page":"e50005","DOI":"10.1371\/journal.pone.0050005","article-title":"Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K\/Akt and MEK\/ERK pathway","volume":"7","author":"Ramakrishnan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jss.2016.08.014_bib32","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib33","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2016.08.014_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-7-41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in\u00a0vitro study","volume":"7","author":"Zhang","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.jss.2016.08.014_bib35","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3346\/jkms.2011.26.12.1563","article-title":"Novel EGFR-TK inhibitor EKB-569 inhibits\u00a0hepatocellular carcinoma cell proliferation by AKT and MAPK pathways","volume":"26","author":"Kim","year":"2011","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jss.2016.08.014_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2013.05.010","article-title":"Synthetic lethal interaction between PI3K\/Akt\/mTOR and Ras\/MEK\/ERK pathway inhibition in rhabdomyosarcoma","volume":"337","author":"Guenther","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jss.2016.08.014_bib37","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/bjc.2012.70","article-title":"The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition","volume":"106","author":"Haagensen","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2016.08.014_bib38","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-07-0148","article-title":"Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein","volume":"6","author":"Katayama","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jss.2016.08.014_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","article-title":"Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma","volume":"5","author":"Zhai","year":"2013","journal-title":"World J Hepatol"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480416302748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480416302748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T05:18:15Z","timestamp":1532063895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480416302748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0022480416302748"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2016.08.014","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2016.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}